HIKAL Annual Report is a must read for everyone tracking the CDMO/API/Intermediates industry.
HIKAL being a hybrid player, their Annual Report insights on Pharma, Animal Health and Crop
More from Saket Reddy
DEEPAKNTR
Double Top Buy & T20 Pattern - Bullish above 2189.89 daily close on 1% Box Size Chart. https://t.co/dEAqzILJj4
Double Top Buy & T20 Pattern - Bullish above 2189.89 daily close on 1% Box Size Chart. https://t.co/dEAqzILJj4
DEEPAKNTR
— Saket Reddy (@saketreddy) March 30, 2021
Double Top Buy & ABC Breakout above 1608.64 daily close on 1% Box size chart & Double Top Buy active on 3% Box size chart.
2000 Coming! https://t.co/ifywtsGM0S pic.twitter.com/VM7TneVwOr
In these kind of stocks, ATH Breakout is usually the best entry.
Don't try bottom fishing and value buying as time correction can take away a lot of opportunity cost.
Just let it give a monthly or weekly close above ATH.
Don't try bottom fishing and value buying as time correction can take away a lot of opportunity cost.
Just let it give a monthly or weekly close above ATH.
ABBOTINDIA
— Saket Reddy (@saketreddy) May 8, 2021
A breakout in the offing? pic.twitter.com/rnpcsQ616a
HAVELLS
Double Top Buy above 1485.56 daily close on 1% Box Size chart. https://t.co/zY8JwRIZUu
Double Top Buy above 1485.56 daily close on 1% Box Size chart. https://t.co/zY8JwRIZUu
HAVELLS
— Saket Reddy (@saketreddy) August 30, 2021
Double Top Buy, Super Pattern - Bullish & T20 Pattern - Bullish above 1266.91 daily close on 1% Box Size chart. https://t.co/78Tb2dKZkm pic.twitter.com/4lWz25jGgk
More from Hikal
Key insights from Hikal
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
Hikal: Strong
— JST Investments (@JstInvestments) August 5, 2021
\U0001f9ea Rev up 27% YoY
\U0001f9ea 22% EBITDA margin
\U0001f9ea Pat of 50crs
\U0001f9ea Growth across both pharmaceuticals & crop protection.#Q1withJST #Pharma pic.twitter.com/8lFo68KzPe